SEC Form 4 · accession 0001209191-18-005206
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Margaret G McGlynn
Director
Period of report
Jan 22, 2018
Accepted (ET)
Jan 24, 2018 · 5:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 22, 2018 | M | 10,000 | $59.55 | A | 16,217 | D | |
| Common Stock | Jan 22, 2018 | S | 10,000 | $160.00 | D | 6,217 | D | |
| Common Stock | Jan 23, 2018 | M | 10,000 | $59.55 | A | 16,217 | D | |
| Common Stock | Jan 23, 2018 | S | 10,000 | $165.00 | D | 6,217 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $59.55 | Jan 22, 2018 | M | 10,000 | D | — | May 31, 2022 | Common Stock | 10,000 | 10,000 | D |
| Stock Option (Right to Buy)F2 | $59.55 | Jan 23, 2018 | M | 10,000 | D | — | May 31, 2022 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Ms. MsGlynn's company-approved trading plan under Rule 10b5-1.
- F2Fully vested.